Stock Analysis

China Tian Yuan Healthcare Group Full Year 2024 Earnings: HK$0.086 loss per share (vs HK$0.039 loss in FY 2023)

SEHK:557
Source: Shutterstock
Advertisement

China Tian Yuan Healthcare Group (HKG:557) Full Year 2024 Results

Key Financial Results

  • Revenue: HK$26.8m (down 41% from FY 2023).
  • Net loss: HK$34.2m (loss widened by 121% from FY 2023).
  • HK$0.086 loss per share (further deteriorated from HK$0.039 loss in FY 2023).
    earnings-and-revenue-history
    SEHK:557 Earnings and Revenue History March 31st 2025

    All figures shown in the chart above are for the trailing 12 month (TTM) period

    China Tian Yuan Healthcare Group shares are down 2.2% from a week ago.

    Risk Analysis

    You should learn about the 2 warning signs we've spotted with China Tian Yuan Healthcare Group.

    New: AI Stock Screener & Alerts

    Our new AI Stock Screener scans the market every day to uncover opportunities.

    • Dividend Powerhouses (3%+ Yield)
    • Undervalued Small Caps with Insider Buying
    • High growth Tech and AI Companies

    Or build your own from over 50 metrics.

    Explore Now for Free

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About SEHK:557

China Tian Yuan Healthcare Group

An investment holding company, provides healthcare related services in Hong Kong, Korea, the People’s Republic of China, and Korea.

Mediocre balance sheet and slightly overvalued.

Advertisement